Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: A new strategy to avoid ovarian hyperstimulation syndrome

Fertility and Sterility

Volumn 95, Issue 3, 2011, Pages 1137-1140

  Herrero, Leyre ^a   Pareja, Sandra ^a   Losada, Carolina ^a   Cobo, Ana Cristina ^b   Pellicer, Antonio ^b   Garcia Velasco, Juan Antonio ^a,c  

^a IVI Madrid   (Spain)

^b IVI Valencia   (Spain)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

coasting; HCG; oocyte vitrification; Ovarian hyperstimulation

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; EMBRYO; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HIGH RISK PATIENT; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OOCYTE MATURATION; OVARIAN PRESERVATION; OVARY HYPERSTIMULATION; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; CHORIONIC GONADOTROPIN; CRYOPRESERVATION; EMBRYO TRANSFER; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; RISK FACTORS; SPERM INJECTIONS, INTRACYTOPLASMIC; VITRIFICATION;

EID: 79951947677     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.09.040     Document Type: Article

References (38)

1. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproduction technology: definition of high risk groups. Hum Reprod 1991;6:1395-9.
2. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:275-89. (Pubitemid 36827064)
3. Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco JA. Vascular endothelial cadherin regulates vascular permeability: implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2007;92:314-21. (Pubitemid 46067549)
4. Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonist of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 1990;53:502-9. (Pubitemid 20093615)
5. Garcia-Velasco JA, Isaza V, Quea G, Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil Steril 2006;85:547-54.
6. Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertil Steril 2007;88:1382-8. (Pubitemid 350030972)
7. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002;87:709-15. (Pubitemid 34158241)
8. Alvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210-4. (Pubitemid 351696781)
9. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-7. (Pubitemid 47236352)
10. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007;15:408-12. (Pubitemid 47565008)
11. Giles J, Requena A, Garcia-Velasco JA, Pacheco A, Pellicer J, Pellicer A. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. Fertil Steril 2009;91:1366-9.
12. Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online 2005;11:300-8. (Pubitemid 41269568)
13. Cobo A, Bellver J, Domingo J, Pérez S, Crespo J, Pellicer A, et al. New options in assisted reproduction technology: the Cryotop method of oocyte vitrification. Reprod Biomed Online 2008;17:68-72.
14. Isaza V, Garcia-Velasco JA, Aragones M, Remohi J, Simon C, Pellicer A. Oocyte and embryo quality after coasting: the experience from oocyte donation. Hum Reprod 2002;17:1777-82. (Pubitemid 34790300)
15. Garcia-Velasco JA, Isaza V, Vidal C, Landazábal A, Remohí J, Simón C, et al. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 2001;16:2533-9. (Pubitemid 34007467)
16. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist Ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 2000;15:1965-8.
17. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, GrØndahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005;20:1213-20.
18. Kol S, Muchtar M. Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further research. Reprod Biomed Online 2005;10:575-7. (Pubitemid 40655275)
19. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNF alpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006;21:1260-5.
20. Engmann L, Siano D, Schmidt D, Nulsen J, Maier D, Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 2006;13:639-44. (Pubitemid 44760886)
21. Engman L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84-91.
22. Orvieto R, Rabinson J, Meltzer S, Homburg R, Anteby E, Zohav E. GnRH agonist versus GnRH antagonist in ovarian stimulation: is the emperor naked? Clin Exp Obstet Gynecol 2006;33:197-9.
23. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;2:159-68. (Pubitemid 43239269)
24. Díaz I, Guillén A, Pacheco A, Requena A, Garcia-Velasco JA. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination. J Reprod Med 2008;53:33-9. (Pubitemid 351219777)
25. Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? J Assist Reprod Genet 2008;25:63-6.
26. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005;20:2887-92. (Pubitemid 41508652)
27. Yano T, Yano N, Matsumi H, Morita Y, Tsutsumi O, Schally AV, et al. Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development. Horm Res 1997;48:35-41. (Pubitemid 27352731)
28. Takekida S, Deguchi J, Samoto T, Matsuo H, Maruo T. Comparative analysis of the effects of gonadotropin-releasing hormone agonist on the proliferative activity, apoptosis, and steroidogenesis in cultured porcine granulosa cells at varying stages of follicular growth. Endocrine 2000;12:61-7. (Pubitemid 30333812)
29. DiLuigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril 2010;94:1111-4.
30. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertil Steril 2007;88:237-9. (Pubitemid 47001391)
31. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009;18:630-4.
32. Castillo JC, Dolz M, Bienvenido E, Abad L, Casañ E, Bonilla-Musoles F. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online 2010;20:175-81.
33. Cobo A, Kuwayama M, Perez S, Ruiz A, Pellicer, Remohi J. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril 2007;89:1657-64. (Pubitemid 351749628)
34. Lucena E, Bernal DP, Lucena C, Rojas A, Moran A, Lucena A. Successful ongoing pregnancies after vitrification of oocytes. Fertil Steril 2006;85:108-11. (Pubitemid 43063431)
35. Queenan JT. Embryo freezing to prevent ovarian hyperstimulation syndrome. Mol Cell Endocrinol 2000;27:79-83.
36. Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod 2007;22:1348-52. (Pubitemid 47062805)
37. Nachtigall RD, Dougall KM, Lee M, Harrington J, Becker G. What do patients want? Expectations and perceptions of IVF clinic information and support regarding frozen embryo disposition. Fertil Steril 2010 [Epub ahead of print].
38. Heng BC. Oocyte cryopreservation as an alternative to embryo cryopreservation - some pertinent ethical concerns. Reprod Biomed Online 2007;14:402-3. (Pubitemid 46463641)